Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial.
Ayurveda
Coronavirus
Covid-19 pandemic
Flu like symptoms
Hospital stay
RT-PCR
SARS-CoV-2
Viral illness
Journal
Journal of Ayurveda and integrative medicine
ISSN: 0975-9476
Titre abrégé: J Ayurveda Integr Med
Pays: United States
ID NLM: 101551404
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
received:
07
07
2022
revised:
08
02
2023
accepted:
08
07
2023
medline:
18
11
2023
pubmed:
18
11
2023
entrez:
17
11
2023
Statut:
aheadofprint
Résumé
Medicines in indigenous systems such as Ayurveda have strong antimicrobial activity but double-blind randomized control trials are infrequent in this system of medicine. The efficacy of a new ayurvedic formulation was evaluated during the pandemic. 150 mild-moderate COVID-19 patients were enrolled and randomized in 1:1 to NAOQ19 and placebo group. RT-PCR was done on Day 3, 5 and 7. CBC, CRP, LFT, and KFT were assessed at baseline and exit. Duration of hospital stay was noted and clinical assessment was also performed. The results demonstrated more people turning RT-PCR negative in the NAOQ19 group compared to the placebo group on day 3 (p-value = 0.033). The mean time duration to turn RT-PCR negative was significantly lower in the NAOQ19 group (4.6 days) compared to placebo group (5.2 days) (p-value = 0.018). There was significant reduction in hospital stay among patients in the NAOQ19 arm who were discharged earlier (5.6 days) compared to placebo group (6.4 days) (p-value = 0.046). Patients in NAOQ19 arm did not show any adverse life-threatening events. The ayurvedic preparation given along with standard of care therapy reduced the duration of hospital stay and there was earlier conversion to RT-PCR negative.The integrated approach can help to reduce patient workload in the hospitals as well as limit the transmission of the virus in the community. CTRI/2021/05/033790.
Sections du résumé
BACKGROUND
BACKGROUND
Medicines in indigenous systems such as Ayurveda have strong antimicrobial activity but double-blind randomized control trials are infrequent in this system of medicine. The efficacy of a new ayurvedic formulation was evaluated during the pandemic.
METHODS
METHODS
150 mild-moderate COVID-19 patients were enrolled and randomized in 1:1 to NAOQ19 and placebo group. RT-PCR was done on Day 3, 5 and 7. CBC, CRP, LFT, and KFT were assessed at baseline and exit. Duration of hospital stay was noted and clinical assessment was also performed.
RESULT
RESULTS
The results demonstrated more people turning RT-PCR negative in the NAOQ19 group compared to the placebo group on day 3 (p-value = 0.033). The mean time duration to turn RT-PCR negative was significantly lower in the NAOQ19 group (4.6 days) compared to placebo group (5.2 days) (p-value = 0.018). There was significant reduction in hospital stay among patients in the NAOQ19 arm who were discharged earlier (5.6 days) compared to placebo group (6.4 days) (p-value = 0.046). Patients in NAOQ19 arm did not show any adverse life-threatening events.
CONCLUSION
CONCLUSIONS
The ayurvedic preparation given along with standard of care therapy reduced the duration of hospital stay and there was earlier conversion to RT-PCR negative.The integrated approach can help to reduce patient workload in the hospitals as well as limit the transmission of the virus in the community.
STUDY REGISTRATION
BACKGROUND
CTRI/2021/05/033790.
Identifiants
pubmed: 37976809
pii: S0975-9476(23)00094-3
doi: 10.1016/j.jaim.2023.100778
pmc: PMC10684801
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100778Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Phytother Res. 2020 Nov;34(11):2911-2920
pubmed: 32430996
Pharmaceuticals (Basel). 2023 Apr 23;16(5):
pubmed: 37242424
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100393
pubmed: 33897204
J Biomol Struct Dyn. 2021 Sep;39(15):5668-5681
pubmed: 32643552
Ayu. 2020 Apr-Jun;41(2):107-116
pubmed: 34908795
Environ Sci Pollut Res Int. 2021 Oct;28(40):55925-55951
pubmed: 34491498
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100380
pubmed: 33519134
Platelets. 2023 Dec;34(1):2184183
pubmed: 36883692
World J Methodol. 2022 May 20;12(3):132-147
pubmed: 35721243
Lancet. 2022 Jan 29;399(10323):412-413
pubmed: 35065007
Nat Immunol. 2022 Feb;23(2):275-286
pubmed: 35102342
Trials. 2021 Feb 11;22(1):130
pubmed: 33573696
Front Mol Biosci. 2020 Dec 23;7:613401
pubmed: 33425994
Osong Public Health Res Perspect. 2022 Oct;13(5):316-327
pubmed: 36328236
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100365
pubmed: 33100779
Altern Ther Health Med. 2023 May;29(4):134-139
pubmed: 35951065
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100350
pubmed: 32837101
Front Med (Lausanne). 2022 Feb 16;9:761655
pubmed: 35252231
Phytochem Anal. 2021 Jul;32(4):629-639
pubmed: 33167083
Front Pharmacol. 2021 Oct 14;12:746729
pubmed: 34721035
Int J Gen Med. 2023 Jan 17;16:185-191
pubmed: 36691650
J Biomol Struct Dyn. 2022 Jan;40(1):190-203
pubmed: 32851919
Virusdisease. 2021 Mar;32(1):65-77
pubmed: 33778129
Phytomedicine. 2021 Apr;84:153494
pubmed: 33596494
Horm Mol Biol Clin Investig. 2021 Jul 30;42(4):343-344
pubmed: 34332513
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Contemp Clin Trials Commun. 2021 Jun;22:100755
pubmed: 33728385
Lancet. 2003 Jun 14;361(9374):2045-6
pubmed: 12814717
J Nat Prod. 2021 Apr 23;84(4):1261-1270
pubmed: 33844528
Front Med (Lausanne). 2021 May 07;8:672629
pubmed: 34026798
J Med Chem. 2005 Feb 24;48(4):1256-9
pubmed: 15715493
Eur J Pharmacol. 2020 Nov 5;886:173551
pubmed: 32931783
J Biomol Struct Dyn. 2022;40(21):11070-11081
pubmed: 34431451
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100424
pubmed: 33746457
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100581
pubmed: 35753154
J Neuropsychiatry Clin Neurosci. 2023 Winter;35(1):12-27
pubmed: 35872617